BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 30815760)

  • 1. New and Potential Treatments for Atopic Dermatitis: Biologicals and Small Molecules.
    Sánchez-Borges M; Capriles-Hulett A; Ortega-Martell JA; Zubeldia IA
    Curr Allergy Asthma Rep; 2019 Feb; 19(3):18. PubMed ID: 30815760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current novel approaches in systemic therapy of atopic dermatitis: specific inhibition of cutaneous Th2 polarized inflammation and itch.
    Werfel T; Biedermann T
    Curr Opin Allergy Clin Immunol; 2015 Oct; 15(5):446-52. PubMed ID: 26308331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy.
    D'Erme AM; Romanelli M; Chiricozzi A
    Drug Des Devel Ther; 2017; 11():1473-1480. PubMed ID: 28553077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atopic dermatitis phenotypes and the need for personalized medicine.
    Cabanillas B; Brehler AC; Novak N
    Curr Opin Allergy Clin Immunol; 2017 Aug; 17(4):309-315. PubMed ID: 28582322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dupilumab in the treatment of moderate-to-severe atopic dermatitis.
    Kraft M; Worm M
    Expert Rev Clin Immunol; 2017 Apr; 13(4):301-310. PubMed ID: 28165826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EAACI Biologicals Guidelines-dupilumab for children and adults with moderate-to-severe atopic dermatitis.
    Agache I; Akdis CA; Akdis M; Brockow K; Chivato T; Del Giacco S; Eiwegger T; Eyerich K; Giménez-Arnau A; Gutermuth J; Guttman-Yassky E; Maurer M; Ogg G; Ong PY; O'Mahony L; Schwarze J; Warner A; Werfel T; Palomares O; Jutel M
    Allergy; 2021 Apr; 76(4):988-1009. PubMed ID: 33538044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Therapeutic Approaches and Targets for the Treatment of Atopic Dermatitis.
    Pescitelli L; Rosi E; Ricceri F; Pimpinelli N; Prignano F
    Curr Pharm Biotechnol; 2021; 22(1):73-84. PubMed ID: 32525769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologic Therapy for Atopic Dermatitis: Moving Beyond the Practice Parameter and Guidelines.
    Boguniewicz M
    J Allergy Clin Immunol Pract; 2017; 5(6):1477-1487. PubMed ID: 29122151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of biologicals in cutaneous allergies - present and future.
    Makris MP; Papadavid E; Zuberbier T
    Curr Opin Allergy Clin Immunol; 2014 Oct; 14(5):409-16. PubMed ID: 25102106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type 2 Inflammation: Atopic Dermatitis, Asthma, and Hypereosinophilia Successfully Treated With Dupilumab.
    Benzecry V; Pravettoni V; Segatto G; Marzano AV; Ferrucci S
    J Investig Allergol Clin Immunol; 2021 Jun; 31(3):261-263. PubMed ID: 32732182
    [No Abstract]   [Full Text] [Related]  

  • 11. [Ocular symptoms associated with dupilumab in atopic dermatitis].
    Voorberg AN; Oosterhaven JAF; Wijdh RHJ; de Bruin-Weller MS; Schuttelaar MLA
    Ned Tijdschr Geneeskd; 2019 Mar; 163():. PubMed ID: 30945835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next?
    van der Schaft J; Thijs JL; de Bruin-Weller MS; Balak DMW
    Curr Opin Allergy Clin Immunol; 2019 Aug; 19(4):341-349. PubMed ID: 31145194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in atopic dermatitis.
    Dinakar C; Fineman SM; Tilles SA
    Ann Allergy Asthma Immunol; 2018 Jan; 120(1):8-9. PubMed ID: 29273133
    [No Abstract]   [Full Text] [Related]  

  • 14. Towards personalized treatment in atopic dermatitis.
    van der Schaft J; Thijs JL; Garritsen FM; Balak D; de Bruin-Weller MS
    Expert Opin Biol Ther; 2019 May; 19(5):469-476. PubMed ID: 30768375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and Future Monoclonal Antibodies in the Treatment of Atopic Dermatitis.
    Chun PIF; Lehman H
    Clin Rev Allergy Immunol; 2020 Oct; 59(2):208-219. PubMed ID: 32617839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The IL-13-OVOL1-FLG axis in atopic dermatitis.
    Furue K; Ito T; Tsuji G; Ulzii D; Vu YH; Kido-Nakahara M; Nakahara T; Furue M
    Immunology; 2019 Dec; 158(4):281-286. PubMed ID: 31509236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies for Successful Management of Severe Atopic Dermatitis.
    Brar KK; Nicol NH; Boguniewicz M
    J Allergy Clin Immunol Pract; 2019 Jan; 7(1):1-16. PubMed ID: 30598172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of dupilumab in the treatment of atopic diseases.
    Thibodeaux Q; Smith MP; Ly K; Beck K; Liao W; Bhutani T
    Hum Vaccin Immunother; 2019; 15(9):2129-2139. PubMed ID: 30785362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Onset of Schamberg Disease and Resolution of Alopecia Areata During Treatment of Atopic Dermatitis With Dupilumab.
    Szekely S; Vaccari D; Salmaso R; Belloni-Fortina A; Alaibac M
    J Investig Allergol Clin Immunol; 2021 Feb; 31(1):65-66. PubMed ID: 32490817
    [No Abstract]   [Full Text] [Related]  

  • 20. Real-world persistence with dupilumab among adults with atopic dermatitis.
    Silverberg JI; Guttman-Yassky E; Gadkari A; Kuznik A; Mallya UG; Mastey V; Zhang H; Chen Z; Chen C; Korotzer A; Sierka D; Fenton MC; Kaur M; Jalbert JJ
    Ann Allergy Asthma Immunol; 2021 Jan; 126(1):40-45. PubMed ID: 32739313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.